Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ceptaris Therapeutics

Request full access

Pharmaceutical company developing therapeutics for symptoms of early-stage mycosis fungoides

Malvern, United StatesFounded 2002Biotech & Life Sciences

About Ceptaris Therapeutics

Ceptaris Therapeutics, Inc. was a specialty pharmaceutical company founded in 2002 and formerly known as Yaupon Therapeutics. The company focused on developing and commercializing treatments for dermatological and central nervous system diseases.

The company's primary asset was VALCHLOR® (mechlorethamine) gel, a proprietary formulation developed for the topical treatment of early-stage mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma. Prior to VALCHLOR, patients depended on non-standardized, pharmacy-compounded preparations of mechlorethamine. Ceptaris's product was developed to provide a standardized, FDA-reviewed treatment option. VALCHLOR is an alkylating drug applied once daily as a thin film to affected skin areas, designed to inhibit the proliferation of cancer cells.

The company's business model was centered on obtaining regulatory approval for VALCHLOR and then commercializing it for specialists in dermatology and oncology. A significant milestone was achieved in August 2013, when the U.S. Food and Drug Administration (FDA) granted marketing approval for VALCHLOR for Stage IA and IB mycosis fungoides-type CTCL in patients who have received prior skin-directed therapy. This approval was a pivotal event for the company, following a previous Complete Response Letter from the FDA which had requested additional information.

In July 2013, anticipating the drug's approval, Swiss biopharmaceutical company Actelion Ltd entered into an agreement to acquire Ceptaris. The acquisition was contingent on the FDA's approval of VALCHLOR. The deal involved an upfront payment of $25 million, with an additional $225 million paid to Ceptaris' shareholders upon the transaction's closing in September 2013, following the FDA's green light. The agreement also included potential future payments based on sales and commercial milestones. The acquisition allowed Actelion to enter the oncology market and leverage its expertise in rare diseases to commercialize VALCHLOR.

Source: Dealroom company data

At a glance

Status
Acquired
Employees
1
Open positions
None listed
Dealroom signal
24.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Jul 2013 $250M $250M Actelion Pharmaceuticals —
SERIES D✓Equity / VC Jun 2012 $10M $40M Burrill · BioAdvance · Aperture Venture Partners · Palo Alto Investors —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Ceptaris Therapeutics website traffic

Latest recorded traffic for Ceptaris Therapeutics is 0 monthly website visits. Ceptaris Therapeutics's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ceptaris Therapeutics in the Malvern ecosystem

Live from Dealroom

The Ceptaris Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Ben Franklin Technology Partners of Southeastern Pennsylvania
  • BioAdvance

Series B and later7 investors entered at this stage

Other known investors4 additional known investors

  • Actelion Pharmaceuticals
  • Aperture Ventures Partners
  • Mid-Atlantic Angel Group
  • Project Liberty Digital Incubator
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Malvern HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ceptaris Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ceptaris Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.